BRAIN CANCER

HER2 Breast Cancer

BREAST CANCER

Bladder Cancer

Prostate Cancer

Renal Cell Carcinoma

GENITOURINARY CANCERS

Liquid Biopsies

GENOMIC TESTING

Colorectal Cancer

GIST

Gastric Cancer

GI CANCERS

Cervical Cancer

Endometrial Cancer

Ovarian Cancer

GYNECOLOGIC CANCERS

HEAD & NECK CANCERS

Bone Marrow & Stem Cell Transplant

HEMATOLOGY

CAR T-Cell Therapy

IMMUNOTHERAPY

Chronic Lymphocytic Leukemia

Chronic Myeloid Leukemia

LEUKEMIAS

Biomarker-Driven Lung Cancer

EGFR+ Lung Cancer

MET-Targeted Therapy

Small Cell Lung Cancer

LUNG CANCER

DLBCL

Follicular Lymphoma

Mantle Cell Lymphoma

LYMPHOMAS

MPNs

MULTIPLE MYELOMA

NTRK GENE FUSIONS

SARCOMA

Melanoma

SKIN CANCERS

THYROID CANCERS

NEWS

Special Reports

All News

FDA Briefs

Oncology Icons

The Targeted Pulse

Voices from the Field

CONFERENCES

Conference Coverage

Conference Listing

Data Dialogue with the Oncology Brothers

MEDIA

All Videos

Case-Based Peer Perspectives

Evolving Paradigms in Oncology

Expert Perspective Virtual Tumor Board

Interviews

Investigator Perspectives

Medical World News

Personalized Medicine

Pivotal Practice Views with the Oncology Brothers

Podcasts

Speaking Out

PUBLICATIONS

All Publications

Evolving Paradigms

Peers & Perspectives in Oncology

Targeted Therapies in Oncology

CASE-BASED ROUNDTABLE

PARTNERS

RESOURCES

CME/CE

Clinical Trials

Events

Precision Medicine Perspectives

Press Releases

Treatment Resources

SUBSCRIBE

Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted precision medicine strategies.

About Us

Advertise

Contact Us

CureToday.com

CancerNetwork.com

OncLive.com

OncNursingNews.com

Do Not Sell My Information

Privacy

Terms & Conditions

Editorial Board

Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways

Facebook

Linkedin

YouTube

Instagram

Featured Clinical Focus

BTK Inhibitors: In-Focus

Bone Marrow & SCT

EGFR-Positive Lung Cancer

Lung Cancer

Multiple Myeloma

Thyroid Cancers

Clinical Focus

Brain Cancer

Breast Cancer

Gastrointestinal Cancer

Genitourinary Cancers

Gynecologic Cancers

Head & Neck Cancers

Hematology

Leukemias

Lymphomas

Sarcoma

Skin Cancers

Spotlight

Myeloma

Genomic Testing

1rem

Authors

Ingrid A. Mayer, MD, MSCI, discusses patient selection for emerging therapies in patients with ER-positive metastatic breast cancer (mBC). 


Dr. Mayer Discusses Patient Selection for Emerging Therapies in Patients With ER+ mBC

In April of 2024, the FDA’s Oncology Drugs Advisory Committee (ODAC) unanimously approved the use of minimal residual disease (MRD) as an end point for accelerated approval of multiple myeloma therapies. Since then, trial investigators have rapidly adapted to the new paradigm, and new approvals based on MRD are on the horizon.

Additionally, there are more trends in MRD to look out for, including international adoption of the approval end point, updates to FDA guidance on MRD in drug development, and improvements to bone marrow and blood-based assays.

, C. Ola Langren, MD, PhD, professor of medicine and chief of the myeloma division and the Myeloma Institute at the Sylvester Comprehensive Cancer Center at the University of Miami, discussed the continuing impact of the groundbreaking FDA ODAC vote, the future of the Miami Myeloma MRD Meeting, and how researchers plan to continue expanding the role of MRD in multiple myeloma and other hematologic malignancies.

: Could you explain your work supporting the use of MRD as an efficacy end point in in multiple myeloma?

We were part of the work that led to the ODAC vote 12 to 0 in favor of MRD as a regulatory end point

. I pioneered this work 15 years ago when I was at the National Cancer Institute [NCI] at the Intramural Program. We kept on working for many years. When I was at Memorial Sloan Kettering Cancer Center [MSK], we kept on working, and we continued to work here from the Myeloma Institute in Miami. We submitted all the packages to the FDA for their review. That work shows that instead of waiting for progression-free survival [PFS], MRD can be used as an early end point for accelerated approval. MRD negativity is a very strong predictor for clinical outcome—PFS in this case—so that was a very important step for the field.

Going forward, the deliverable is that trials can be done much faster. Instead of enrolling patients in a randomized trial that could take 2 years to complete and then wait another 10 or more years for the data to mature for PFS, you could capture MRD results 1 year after randomization, shrinking 10 to 15 years down to only 2 years of enrollment and 1 year to wait for MRD. After that, if the study is successful in showing higher rates of MRD negativity for a new therapy, that treatment could be approved based on accelerated approval, so patients can get access to new drugs 10 years sooner than just waiting for the clinical outcome. That's a huge step forward for the field and for all the patients.

What developments have there been in the use of MRD as an end point since the ODAC meeting?

Since the ODAC meeting in April of 2024, we have seen a lot of things happening. Many, if not all of the companies have implemented MRD as a coprimary end point. They have also included PFS. The reason you see both is because not every drug may drive the disease all the way down to MRD negativity, so when you develop a trial, you want to make sure you're not putting all the eggs in one basket. The companies will do both MRD and PFS. We have also seen that all the companies that have ongoing trials that used to have only PFS as the primary end point have…negotiated with the FDA to revise or amend their protocols to also include MRD as a coprimary end point. That’s a huge change for the field. Everything ongoing has been updated, and all the new trials have been including [MRD].

What is also going to happen is that the guidance documents from the FDA will presumably be updated whenever the agency is ready. We have worked very closely with the FDA for all these years when we filed the data for the ODAC review last year, and we have had multiple conversations after the ODAC [meeting]. They have told us that they are working internally, but it also has to go through all their different layers before it becomes an official document.

Lastly, it has also triggered [researchers in] a lot of other diseases to think about [using MRD]. The week after we went to ODAC, I got multiple emails and phone calls from different other disease areas asking if I could help develop MRD for many other diseases. I work on myeloma, but I'm happy to help and give feedback. We also published a review article that came out in January in 

 that summarizes the entire blueprint of how MRD could become an early end point for accelerated approval.

 My intention was to make sure that when people reach out for other diseases, we can point to this paper, because it has…the big picture as well as all the details of how the work has been done.

What is needed for the new FDA guidance on MRD to be released and what impact will it have?

The guidance document the FDA came out with for MRD most recently came out in 2020.

 In that document, they said that MRD can be used for surrogate end points in 2 different ways. One is that it is the end point for the full approval, but it could also be an early end point for accelerated approval. There are criteria for what an MRD end point has to include. There has to be a plausibility on a biological note, there have to be correlations on an individual patient level, and there has also to be evidence from clinical trials. There is a very specific list with criteria the FDA has spelled out, and that's available online for anyone to download.

That document came out in 2020 but the FDA ODAC meeting where MRD was voted 12 to 0 in favor of being an early end point for accelerated approval in myeloma [came] 4 years after this document, so there will presumably be an updated version of the guidance document based on that. But these documents don't come out once a week or once a month or even once a year. It takes a long time for the federal government to make sure that the guidance document is not something they need to go back and correct right away. They want to think it through. It goes through their medical review, their statistical review, legal reviews, and reviews for guidance documents. Going through all these different processes to ensure this document is a very valid document that is going to be received well, and it's also it's going to last for a while. That's why it takes a lot of time.

It’s the same as when we write clinical guidelines. We write different types of guidelines in the field, it takes a lot of time, and people also have to agree, so that can take some little extra time. I'm sure there are a lot of internal discussions on a lot of the details, but it will happen. I think it's going to come out…maybe in 6 to 12 months we'll see.

The guidance document is the general guidance for the use and the development of MRD in the setting as an early end point for accelerated approval, and that would be applicable to all the other diseases. For myeloma, we already have the ODAC vote 12 to 0 in favor of MRD being an early end point for accelerated approval in multiple myeloma. The companies have already revised their existing protocols and gone back to the FDA…and when they write new protocols, they [include MRD]. I think the guidance document is going to be a document that probably can save some of those discussions between individual companies and the FDA, but mostly I think it's going to help other diseases.

Another dimension of the complexity for drug companies that develop these trials [is that] they want to make sure the drugs are reviewed and approved so they can be available for patients, and this is a complicated process that usually includes many different countries around the world. From a drug company perspective, if you were to develop a study where PFS and MRD negativity are the end points here in the United States, and you get a readout for MRD after 2 or 3 years, if Europe has not yet approved MRD, then you have to wait for PFS. If you picked MRD as the only end point, you could think of a scenario where the drug could get approved in the United States, but that trial would not be valid in Europe until the regulatory agency in Europe has agreed that MRD is an end point.

We have also worked with the European Medicines Agency [EMA], and we have submitted documents to them as well for their review. But there are other regulatory agencies as well, and the EMA has not yet officially come back with their standing on this. It’s a very long and convoluted process, but the field is moving forward, and this gives you some further insights on what's going on behind the scenes.

Which trial regimens could get FDA approval based on showing MRD negativity?

The most recent trial that has read out where MRD was a coprimary end point is the CEPHEUS trial [NCT03652064].

 This is for patients [who] are newly diagnosed without the use of transplantation using a 4-drug vs a 3-drug combination. This is daratumumab [Darzalex]-based therapy, and it was the VRd [bortezomib (Velcade), lenalidomide (Revlimid), and dexamethasone] regimen with or without daratumumab. That trial was written in a very visionary way, and the sponsor Johnson & Johnson took a calculated risk when they wrote the protocol when they put MRD as a coprimary endpoint, because at the time the study was going to read out, MRD had not yet been voted for by ODAC. No one knew that there would be an ODAC meeting…when the study was launched.

I think it was a bold move, but now, when the ODAC meeting has happened, the data have come to the FDA. Now, all the stars are aligned. I think we will see more and more studies reading out [based] on MRD. There's a long list of trials with all the bispecifics, [etc]. All these things have already happened, and we will see more and more trials reading out this way.

Could you discuss the goals of the ADVANCE trial (NCT04268498) using MRD to guide treatment?

I designed a study when I led a program at MSK called MANHATTAN. This was the first 4-drug combination for newly diagnosed patients using KRd [carfilzomib (Kyprolis), lenalidomide, and dexamethasone] as a backbone with daratumumab. The MANHATTAN study showed that we could achieve MRD negativity in over 70% of patients, even in the absence of bone marrow transplantation.

 That study led to Dara-KRd coming into the NCCN guidelines as a category 2A approved therapy, [which] gave patient access. We have worked to test this regimen compared with the KRd regimen that we developed 10 years earlier when I was at the NCI, so we wanted to do a randomized trial of KRd vs Dara-KRd.

MRD is an early end point for [the ADVANCE] study, so it reads out after the completion of 8 cycles. The patient gets 4 cycles, then they can collect the stem cells and do another 4 cycles if patients are MRD negative. The protocol would keep patients on maintenance with a deferred transplant. If patients are completing the 8 cycles and they are MRD positive, if they have collected stem cells, the study would recommend a patient consider transplantation. A patient can go on the trial even if they don't collect the stem cells. It's open for both transplant-eligible and transplant-ineligible patients, because the primary end point is to determine MRD negativity after 8 cycles. These results have been submitted as an abstract, and 

they will be presented at the 2025 American Society of Clinical Oncology Annual Meeting

What was discussed at the Miami Myeloma MRD Meeting this year?

We started having annual meetings focusing on MRD in myeloma 11 years ago, and I made a pledge saying that we're going to have this meeting once a year until the FDA approves MRD as an end point for drug approval in multiple myeloma. We delivered on that in April 2024, but there have also been a lot of developments in terms of new assays, blood-based technologies, and different types of approaches in the bone marrow. There are imaging-based technologies as well, and of course, a lot of other questions that come into play in study design. There are all the patient perspectives and, beyond drug approval, MRD could probably also be used for treatment decisions.

The PERSEUS trial [NCT03710603] was published last year in the 

 showing MRD negativity was used in that trial to step down on the intensity of maintenance there.

 We see more and more trials having MRD as a tool to step up or step down the intensity of treatment.

So, we have decided to keep on going with this meeting. We talked to the FDA extensively about this, and the FDA has encouraged us to keep this meeting going, to keep the group together, because we have been inclusive for all these years. For more than a decade, we have done the meeting. We had the meeting in April 2025 in beautiful Miami for the eleventh year in a row, and we had representation from drug companies, academia, and patient organizations. We had invited the government, but because of some of the changes in Washington, DC, they were unable to join this year in person. But we had review presentations…based on their data. I would say we have all the bases covered this year as well. We had 90 people in person, and we had 807 attendees online, so almost 1000 people attended this workshop.

We got extremely good feedback. We continue to work on developing new technologies for tracking using blood-based technologies, and we also try to leverage the bone marrow–based technologies. People have already asked us for the date of the 2026 [meeting]. We are just about to sign the contract for the venue, so we will probably continue once a year for a long time, for many more years to come.

1. Landgren O, Devlin SM. Minimal residual disease as an early endpoint for accelerated drug approval in myeloma: a roadmap. 

. 2025;6(1):13-22. doi:10.1158/2643-3230.BCD-24-0292

2. Hematologic malignancies: regulatory considerations for use of minimal residual disease in development of drug and biological products for treatment. FDA. January 24, 2020. Accessed May 5, 2025. 

3. Usmani SZ, Facon T, Hungria V, et al. Daratumumab plus bortezomib, lenalidomide and dexamethasone for transplant-ineligible or transplant-deferred newly diagnosed multiple myeloma: the randomized phase 3 CEPHEUS trial. 

. 2025;31(4):1195-1202. doi:10.1038/s41591-024-03485-7

4. Landgren O, Hultcrantz M, Diamond B, et al. Safety and effectiveness of weekly carfilzomib, lenalidomide, dexamethasone, and daratumumab combination therapy for patients with newly diagnosed multiple myeloma: the manhattan nonrandomized clinical trial. 

. 2021;7(6):862-868. doi:10.1001/jamaoncol.2021.0611

5. Sonneveld P, Dimopoulos MA, Boccadoro M, et al; PERSEUS Trial Investigators. Daratumumab, bortezomib, lenalidomide, and dexamethasone for multiple myeloma. 

. 2024;390(4):301-313. doi:10.1056/NEJMoa2312054

In an interview with Targeted Oncology, C. Ola Langren, MD, PhD, discussed the continuing impact of the groundbreaking FDA ODAC vote, the future of the Miami Myeloma MRD Meeting, and how researchers plan to continue expanding the role of MRD in myeloma and other hematologic malignancies. 

Clinical

Myeloma Research Sees Transformation Following ODAC Support For MRD End Point

One year since the FDA’s Oncologic Drugs Advisory Committee (ODAC) 

voted in favor of using minimal residual disease

 (MRD) as an end point to support accelerated approval of drugs, changes are taking place in ongoing clinical trials and cancer research.

The groundbreaking decision led to new trials designed with MRD end points from the start and amendments to existing trial protocols that will enable these trials to report results and submit to the FDA for approval much more quickly.

“If the study is successful in showing higher rates of MRD negativity for a new therapy, that treatment could be approved based on accelerated approval, so patients can get access to new drugs 10 years sooner than just waiting for the clinical outcome. That's a huge step forward for the field and for all the patients,” 

Landgren, professor of medicine and chief of the myeloma division and the Myeloma Institute at the Sylvester Comprehensive Cancer Center at the University of Miami, led the research efforts to support the use of MRD for over a decade.

Additionally, in the past year, the ODAC vote sparked new interest for using MRD more actively in other disease types and improving MRD assays for patients.

MRD serves as a surrogate for clinical outcomes and can be assessed much more rapidly than progression-free survival (PFS). Investigators in ongoing trials have amended their protocols to use both MRD negativity and PFS as coprimary end points for accelerated approval. Investigational therapies that could be evaluated based on MRD include cell therapies, T-cell engagers, antibody-drug conjugates, and small molecule compounds.

“We have also seen that all the companies that have ongoing trials that used to have only PFS as the primary end point have…negotiated with the FDA to revise or amend their protocols to also include MRD as a coprimary end point,” said Landgren. “Everything is ongoing has been updated, and all the new trials have been including [MRD].”

Landgren and other researchers have also presented data to the European Medicines Agency. He said it may take longer for other regulatory agencies to review the data and authorize MRD as an approval end point.

Additionally, researchers in other disease types such as chronic lymphocytic leukemia and lymphoma have expressed interest in following the same path, though they will need to collect the data to support it.

Landgren and Sean M. Devlin, PhD, a biostatistician at Memorial Sloan Kettering Cancer Center in New York, published a review in 

 outlining the long process of developing supporting evidence, which led to the acceptance of MRD by the FDA.

 Two research groups, one from the National Cancer Institute and National Heart, Lung, and Blood Institute and the a second made up of other researchers, developed studies that provided evidence for the use of MRD.

The review noted the utility of overall response rate [ORR] as a meaningful end point in myeloma has decreased as current standard therapies are showing high ORRs comparable to investigational agents with superior PFS. Evaluating MRD during trials provides an alternative that can still yield results more rapidly than mature PFS. MRD at 10

 sensitivity—detecting 1 malignant cell in 100,000 cells—is supported by the FDA as the minimum threshold for MRD analysis, with 10

 sensitivity also being evaluated in trials.

They provided a set of meta-analyses showing MRD negativity was associated with superior PFS and OS outcomes and described their methodology for making meta-analyses to establish it as a surrogate end point for PFS or OS using both trial-level data and patient-level data. Collecting individual patient data was necessary to demonstrate the association between MRD and long-term outcomes was established regardless of patient population, disease setting, or treatment history. This required researchers to gather individual patient data from industry-sponsored trials.

To emphasize the impact of using MRD vs PFS for approval, Landgren and Devlin showed a trial in newly diagnosed multiple myeloma (NDMM) with a comparator arm that had an 84% 4-year PFS rate would require 11.5 years to read out a significant PFS difference with an HR of 0.7, as opposed to only 3.7 years to show a difference in MRD negativity.

There are more avenues to develop MRD in myeloma in the future. Landgren said there have been improvements in the use of bone marrow–based MRD assays as well as the development of blood-based assays and imaging-based technologies that could change how trials are performed.

Additionally, using MRD status to guide further treatment is another approach yielding results. The phase 3 ADVANCE trial (NCT04268498) is investigating the addition of daratumumab (Darzalex) to KRd (carfilzomib [Kyprolis], lenalidomide [Revlimid], and dexamethasone) in NDMM. Patients could receive autologous stem cell transplant if they were MRD-positive and otherwise go directly to maintenance therapy. This trial’s outcomes will be presented at the 2025 American Society of Clinical Oncology Annual Meeting and European Hematology Association Congress.

Read the full interview with Dr Landgren on the changes taking place in myeloma research.

1. Cancer research in the wake of a key FDA decision on minimal residual disease. University of Miami. April 10, 2025. Accessed May 13, 2025. 

2. Landgren O, Devlin SM. Minimal residual disease as an early endpoint for accelerated drug approval in myeloma: a roadmap. 

In the last year, there has been excitement about the use of MRD in multiple myeloma trials and new approaches to assessing clinical outcomes in patients. 

One Year After ODAC Decision: Myeloma Studies Move to Adopt MRD End Point

ASH 2024 Preview for Community Oncologists: The Show and After Show

The American Society of Hematology (ASH) Annual Meeting and Exposition aims to educate oncology providers across an array of hematologic malignancies, with a focus on novel agents, drugs across the FDA pipeline, and more.

, co-hosts Kristie L. Kahl and Andrew Svonavec offer a glimpse at some of the presentations guaranteed to spark one’s curiosity, spur debate, and enhance the field even further. Some key highlights include:

Targeted Oncology co-hosts Kristie L. Kahl and Andrew Svonavec highlight abstracts for community oncologists to look out for at the upcoming ASH Annual Meeting in San Diego, with some additional tidbits to round out the main event.

Ingrid A. Mayer, MD, MSCI

Articles

Latest Updated Articles